External validation of the Oncotype DX breast cancer recurrence score nomogram and development and validation of a novel machine learning-based model to predict postoperative overall survival and guide adjuvant chemotherapy in ER positive, Her-2 negative breast cancer patients: a retrospective cohort study.
Journal:
Frontiers in oncology
Published Date:
May 21, 2025
Abstract
BACKGROUND: This study aims to externally validate the performance of the Oncotype DX (ODX) breast cancer (BC) recurrence score nomogram in predicting adjuvant chemotherapy (ACT) for BC after surgery and subsequently develop a machine learning-based model to predict postoperative overall survival (OS) and guide ACT, demonstrating superior comprehensive performance.
Authors
Keywords
No keywords available for this article.